6/28/23, 11:00 PM LIFE Pathway Feedback Search Clinical Topics Home Studies LIFE LIFE Disease Hypertension Trial question Is losartan-based regimen superior to atenolol-based regimen in patients with essential hypertension and LV hypertrophy? Study design Multi-center Double blinded RCT Population Characteristics of study participants 54.0% female N = 9193 46.0% male 9193 patients (4963 female, 4230 male) Inclusion criteria: patients aged 55-80 years with essential hypertension and LV hypertrophy ascertained by electrocardiography Key exclusion criteria: secondary hypertension, myocardial infarction or stroke within the previous 6 months, HF or LVEF 40% Interventions N=4605 a losartan-based regimen (titrated doses of losartan at 50-100 mg with/without hydrochlorothiazide 12.5-25 mg or other antihypertensive treatment for at least 4 years) N=4588 an atenolol-based regimen (titrated doses of atenolol at 50-100 mg with/without hydrochlorothiazide 12.5-25 mg or other antihypertensive treatment for at least 4 years) https://web.pathway.md/studies/recTdDPQGQUtXkyTM 1/2 6/28/23, 11:00 PM LIFE Pathway Primary outcome Death, myocardial infarction, or stroke 13.0 % 13 11 9.8 % 6.5 % Significant decrease 3.3 % NNT = 50 0.0 % A losartan-based regimen An atenolol-based regimen Significant decrease in death, myocardial infarction, or stroke (11% vs. 13%; aHR 0.87, 95% CI 0.77 to 0.98) Secondary outcomes No significant difference in death from cardiovascular causes (4% vs. 5%; aHR 0.89, 95% CI 0.73 to 1.07) Significant decrease in stroke (5% vs. 7%; aHR 0.75, 95% CI 0.63 to 0.89) Significant decrease in new-onset diabetes (6% vs. 8%; aHR 0.75, 95% CI 0.63 to 0.88) Safety outcomes No significant differences in angioedema, cancer, cough, dizziness, sleep disturbance. Significant differences in bradycardia (1% vs. 9%), cold extremities (4% vs. 6%), hypotension (3% vs. 2%), sexual disturbance (4% vs. 5%). Conclusion In patients aged 55-80 years with essential hypertension and LV hypertrophy ascertained by electrocardiography, a losartan-based regimen was superior to an atenolol-based regimen with respect to death, myocardial infarction, or stroke. Reference Bj rn Dahl f, Richard B Devereux, Sverre E Kjeldsen et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. Open reference URL https://web.pathway.md/studies/recTdDPQGQUtXkyTM 2/2